Roche lung-cancer MetMab drug suffers major blow in Phase III trial
An independent committee has recommended that Roche (RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."
The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.
Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.
If only ARQL had a good management they would be at $5-7 today going ahead with their own NSCLC Ph3.
After listening today ARQL presentation, I concluded that, at this junction, ARQL is NOT an investment grade company. Its management is incompetent and its partners are incapable of conducting successful registration clinical trials. Tivantinib is a promising drug but there is no viable strategy for its development.
There are no any events to drive ARQL stock price up in the next 6-8 months unless KNK will start another Asian Ph III NSCLC trial. There is no strategy to compete with MetMab.
There are other good investment-grade biotech companies capable of rewarding their investors (Biogen, CLVS, ENTA, GILD, SGEN, etc, ) instead of wasting time & money on ARQL.
There is another interesting variable. Kyowa Hakko Kirin just completed their NSCLC trial. The results were not spectacular but there were definite benefits to ITT pts. Analyzing the data, Kyowa Hakko Kirin might be able to get some c-MET high & low pts statistics/results. After all they had 300 NSCLC pts with close to 150 c-MET High pts or 75 of them getting placebo and 75 getting Tiva.
The question: how many pts were tested & analyzed for c-MET status. Based on their analysis, Kyowa Hakko Kirin may initiate their PhIII in NSCLC using C-MET high pts population.